Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
Want to see ZNTL full AI Analyst Report?
Top Page
Zentalis Pharmaceuticals
(NASDAQ:ZNTL)
Select Model
Select Model
Rating:54Neutral
Price Target:
$3.50
▲(148.23% Upside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by weak financial performance (no current revenue, large ongoing losses and negative free cash flow). Offsetting this are constructive technical trend conditions and a series of positive, late-stage clinical and regulatory-path milestones, while valuation metrics are limited due to negative earnings and no dividend.
Positive Factors
Late-stage clinical progress
Advancing azenosertib into a confirmatory Phase 3 while selecting an optimal DENALI dose materially de-risks development timing and regulatory strategy. A parallel confirmatory and accelerated-approval path increases the probability of achieving a clear approval-enabling data set within a multi-quarter horizon.
Negative Factors
No current revenue; large losses
Sustained R&D-driven losses and zero product revenue mean the company remains value-creating only if clinical successes lead to approval or lucrative partnerships. Continued negative cash flow necessitates ongoing financing and elevates execution risk if trial outcomes or timelines slip versus plan.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage clinical progress
Advancing azenosertib into a confirmatory Phase 3 while selecting an optimal DENALI dose materially de-risks development timing and regulatory strategy. A parallel confirmatory and accelerated-approval path increases the probability of achieving a clear approval-enabling data set within a multi-quarter horizon.
Read all positive factors
Zentalis Pharmaceuticals (ZNTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$264.10M
Dividend YieldN/A
Average Volume (3M)716.92K
Price to Earnings (P/E)―
Beta (1Y)3.42
Revenue Growth-100.00%
EPS Growth44.78%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.73
Shares Outstanding71,186,350
10 Day Avg. Volume819,524
30 Day Avg. Volume716,917
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.77K
Enterprise Value/Ebitda-1.96
Forecast
1Y Price Target
$7.00Price Target Upside396.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Zentalis Pharmaceuticals Business Overview & Revenue Model
Company Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1...
How the Company Makes Money
Zentalis is a clinical-stage company and has not had a broadly marketed commercial product in recent periods; as a result, its revenue model has primarily depended on funding its operations through external financing rather than recurring product ...
Zentalis Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 67.42M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -151.00K | 0.00 | 67.42M | 0.00 | 0.00 | 0.00 |
| EBITDA | -136.37M | -144.27M | -186.17M | -247.60M | -225.86M | -207.20M |
| Net Income | -124.13M | -137.06M | -165.84M | -292.19M | -236.81M | -158.72M |
Balance Sheet | ||||||
| Total Assets | 253.07M | 288.97M | 430.34M | 562.03M | 553.46M | 472.02M |
| Cash, Cash Equivalents and Short-Term Investments | 211.76M | 245.89M | 371.08M | 482.92M | 437.37M | 340.13M |
| Total Debt | 34.65M | 39.58M | 42.65M | 45.77M | 47.33M | 45.91M |
| Total Liabilities | 70.39M | 72.76M | 93.15M | 124.64M | 119.43M | 107.54M |
| Stockholders Equity | 182.68M | 216.20M | 337.19M | 437.28M | 433.80M | 363.95M |
Cash Flow | ||||||
| Free Cash Flow | -125.60M | -125.25M | -171.08M | -208.41M | -166.30M | -160.20M |
| Operating Cash Flow | -125.57M | -125.25M | -170.86M | -207.82M | -163.75M | -154.09M |
| Investing Cash Flow | 121.16M | 131.62M | 176.56M | -44.46M | -114.18M | -18.11M |
| Financing Cash Flow | -5.59M | -4.28M | 108.00K | 237.30M | 261.04M | 178.52M |
Zentalis Pharmaceuticals Technical Analysis
Positive
1.41
Price Trends
3.62
Positive
3.06
Positive
2.28
Positive
Market Momentum
<0.01
Positive
45.50
Neutral
14.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZNTL, the sentiment is Positive. The current price of 1.41 is below the 20-day moving average (MA) of 4.04, below the 50-day MA of 3.62, and below the 200-day MA of 2.28, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.50 is Neutral, neither overbought nor oversold. The STOCH value of 14.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZNTL.
Zentalis Pharmaceuticals Risk Analysis
Zentalis Pharmaceuticals disclosed 81 risk factors in its most recent earnings report. Zentalis Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zentalis Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $264.10M | -1.16 | -53.61% | ― | -100.00% | 44.78% | |
53 Neutral | $152.28M | -4.65 | 35.58% | ― | 93.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $283.49M | -1.25 | -147.80% | ― | 1.97% | -25.03% | |
47 Neutral | $25.35M | -0.37 | ― | ― | ― | ― | |
| ― | $91.53M | -9.85 | -65.55% | ― | ― | 19.02% | |
45 Neutral | $314.06M | -0.63 | 309.79% | ― | -35.61% | -68.92% |
* Healthcare Sector Average
ZNTL
Zentalis Pharmaceuticals
3.71
2.50
206.61%
MGNX
MacroGenics
4.46
2.97
199.33%
VTGN
VistaGen Therapeutics
0.64
-1.79
-73.70%
ANIX
Anixa Biosciences
2.73
0.17
6.64%
SPRO
Spero Therapeutics
2.63
1.94
283.94%
SRZN
Surrozen
27.05
19.74
270.04%
Zentalis Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial Disclosures
Zentalis Advances Azenosertib with New Trial Updates
Positive
May 12, 2026
On May 12, 2026, Zentalis Pharmaceuticals reported first-quarter 2026 results and detailed progress in late-stage trials of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. The company selected a 400mg once-daily 5:2 dosing re...
Business Operations and StrategyProduct-Related Announcements
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial
Positive
May 5, 2026
On May 5, 2026, Zentalis Pharmaceuticals announced that the first patient had been dosed in its global Phase 3 ASPENOVA trial of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, marking a key milestone in the late-stage develop...
Business Operations and StrategyProduct-Related Announcements
Zentalis Highlights New Azenosertib Data in Breast Cancer
Positive
Apr 17, 2026
On April 17, 2026, at the American Association for Cancer Research Annual Meeting in San Diego, Zentalis Pharmaceuticals reported new preclinical data for its WEE1 inhibitor azenosertib in triple-negative breast cancer. The studies showed that aze...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Zentalis Advances Azenosertib Dose in DENALI Phase 2
Positive
Apr 9, 2026
On April 9, 2026, Zentalis Pharmaceuticals announced that a prespecified interim analysis from Part 2a of its DENALI Phase 2 trial in Cyclin E1-positive platinum-resistant ovarian cancer supported selecting a 400mg once-daily, 5-days-on/2-days-off...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.